Lumos Pharma Announces New Data and Analysis of 15 Subjects from OraGrowtH212 Trial Presented at the 2023 ESPE Annual Meeting
26 sept. 2023 09h00 HE
|
Lumos Pharma, Inc.
Deconvolution Analysis Shows 60% Increase in GH Secretion, Comparable to Established Values in Normal Children Analysis Shows Annualized Height Velocity Increased ~62% Compared to BaselineData Support...
Lumos Pharma Announced Abstract Accepted for Oral Presentation at the European Society for Paediatric Endocrinology Annual Meeting
14 sept. 2023 08h00 HE
|
Lumos Pharma, Inc.
AUSTIN, Texas, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for moderate Pediatric Growth Hormone...
Lumos Pharma Announces Participation in Investor Conferences in September
07 sept. 2023 16h34 HE
|
Lumos Pharma, Inc.
AUSTIN, Texas, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for moderate Pediatric Growth Hormone...
Independent Panel of Renowned Pediatric Endocrinologists to Discuss Pediatric Growth Hormone Deficiency and the Therapeutic Landscape
22 août 2023 09h00 HE
|
Lumos Pharma, Inc.
AUSTIN, Texas, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for moderate Pediatric Growth Hormone...
Lumos Pharma Reports Second Quarter 2023 Financial Results, Provides Clinical Update
09 août 2023 16h01 HE
|
Lumos Pharma, Inc.
Confirms Timing for Primary Outcome Data Readout for two Phase 2 OraGrowtH Trials in Q4 2023Late Breaking Abstract Accepted for Oral Presentation at ESPE 2023Encouraging Interim Data from OraGrowtH...
Lumos Pharma to Report Second Quarter 2023 Financial Results and Host Conference Call on August 9, 2023
26 juil. 2023 09h00 HE
|
Lumos Pharma, Inc.
AUSTIN, Texas, July 26, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD)...
Lumos Pharma to Participate in the Oppenheimer 2023 Montauk Life Sciences Summit
12 juil. 2023 08h00 HE
|
Lumos Pharma, Inc.
AUSTIN, Texas, July 12, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD)...
Lumos Pharma Announces Departure of Chief Medical Officer
28 juin 2023 16h01 HE
|
Lumos Pharma, Inc.
AUSTIN, Texas, June 28, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for idiopathic Pediatric Growth Hormone...
Lumos to Highlight New LUM-201 Data and Analysis Presented at ENDO 2023 in Virtual KOL Webinar
21 juin 2023 09h00 HE
|
Lumos Pharma, Inc.
Webinar to Review Data Demonstrating Potential Drug Effect and Durable Response Webinar to be held Today June 21, 2023 at 11:00 AM Eastern Time AUSTIN, Texas, June 21, 2023 (GLOBE...
Lumos Pharma to Participate in the Upcoming 2023 BIO International Convention and the Jefferies Healthcare Conference
31 mai 2023 08h00 HE
|
Lumos Pharma, Inc.
AUSTIN, Texas, May 31, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD)...